Strategy analysis

Regulatory measures continue to shape the generics landscape. Cost-containment strategies continue to impact generics.

November 4, 2016

Leading Players in the CMO Market

he following companies are the 10 largest small-molecule contract manufacturing organizations (CMOs) by revenue. While many of the firms also contain biologics businesses, where possible only the relevant small-molecule revenues have been counted.

Disruptive Innovation and the Pharmaceutical Contract Services Sector

With the pharmaceutical sector currently in the middle of such a transformative cycle, are drug developers or the firms providing them with outsourced research or manufacturing services going to find themselves similarly left behind?

CRO Snapshot 2013

An initial study of the only publicly available data detailing clinical trial starts where contract research organizations (CROs) were named as a collaborator in 2013 shows a 10% lessening in work to the service provider industry.

Contract Research Organizations: Health and Wealth in 2013

For public contract research organizations (CROs), the financial story in 2013 was one of solid and steady growth. Revenues grew and company-estimated forecasts for 2014 are also positive.

CRO Snapshot: Clinical Outsourcing in 2012

By any standards, last year was a turbulent one for the pharmaceutical sector. The patent cliff claimed some of the industry’s most profitable properties and with the market share of these drugs losing ground to generics, put even more pressure on the top- and bottom-line performance of key players such as Eli Lilly and AstraZeneca, to name just two of the worst hit.

Such pressure – and the drive to cut fixed costs that goes with it – has been a boon for clinical CROs, which have become increasingly indispensable to the business of drug discovery, as clinical development is outsourced and specialist units, such as clinical laboratories, are offloaded to CROs in long-term guaranteed strategic partnerships.

Argentina Healthcare System Overview

With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

Russia Generics and Biosimilars

Despite high volume uptake, generics still account for only a small proportion of the total market value in Russia, driven by a lack of incentives for generic substitution and the significant originator/generic price differential.

Indonesia Generics and Biosimilars

In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).

France Generics and Biosimilars

Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.

Germany Generics and Biosimilars

The German generics industry is feeling the effects of recent efforts to control drug spending by exerting downward pressure on drug prices.

Indonesia Pharmaceutical Market Dynamics

Kalbe Farma is the leading player by some margin, with a market share of 13% in 2011, while GlaxoSmithKline is the largest foreign player with a 3% share.

The Growing Impact of Real-World Evidence

Real-world evidence (RWE) has become increasingly important in proving the value of drugs and differentiating them from their competition.

July 14, 2017

Russia Pharmaceutical Market Dynamics

With the Russian economy recovering from the recession experienced in 2009, the pharmaceutical market has also returned to growth.

Beyond-the-Pill Services and Solutions: Pharma’s Next Frontier?

Payers and governments are striving toward cost-effective treatment outcomes and more efficient care, and waves of new digital health technologies are offering patients unprecedented opportunities to be more engaged in their own health management.